Italia markets closed

iCAD, Inc. (ICAD)

NasdaqCM - NasdaqCM Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
3,3900+0,1600 (+4,95%)
Al 03:25PM EDT. Mercato aperto.
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente3,2300
Aperto3,2500
Denaro3,4100 x 900
Lettera3,4800 x 800
Min-Max giorno3,1100 - 3,5200
Intervallo di 52 settimane2,9100 - 12,7300
Volume115.577
Media Volume155.466
Capitalizzazione85,387M
Beta (5 anni mensile)1,08
Rapporto PE (ttm)N/D
EPS (ttm)-0,5240
Prossima data utili07 nov 2022 - 11 nov 2022
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1A11,67
  • GlobeNewswire

    iCAD Reports Financial Results For Second Quarter 2022

    Company reports accelerating demand for subscription and cloud-based business models driving long-term recurring revenue opportunities Cancer Detection revenue grew 10.4% compared to the second quarter of 2021 Company to host conference call and webcast today at 4:30 PM ET NASHUA, N.H., Aug. 10, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today reported its financial and operating results for

  • GlobeNewswire

    iCAD to Report Second Quarter 2022 Financial Results on August 10, 2022

    NASHUA, N.H., July 27, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the second quarter ended June 30, 2022, after the market close, and host a conference call at 4:30 PM Eastern Time on August 10, 2022. August 10, 2022 at 4:30 PM ETDomestic: 888-506-0062 International: 973-528-0011 Conference ID: 718241 Webcast: https://www.webcaster4.c

  • GlobeNewswire

    iCAD Presents its Complete Suite of Breast Cancer AI Solutions at the European Congress of Radiology

    Compelling clinical evidence shows ProFound AI Risk accurately identified a high-risk group of women with 32 times higher risk of breast cancer than the general populationNASHUA, N.H., July 13, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that the Company will showcase and demonstrate the complete portfolio of its Breast AI solutions, including ProFound AI®, PowerLook® Density A